Annual Drug Patent Expirations for RYALTRIS
Ryaltris is a drug marketed by Glenmark Specialty and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug.
This drug has seventy patent family members in thirty countries.
The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. One supplier is listed for this compound. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
